MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Cardiovascular
  • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • Whitepapers
  • DeviceTalks
You are here: Home / Blood Management / CathWorks closes $16m Series B to support non-invasive FFR platform

CathWorks closes $16m Series B to support non-invasive FFR platform

October 3, 2017 By Fink Densford Leave a Comment

CathWorks

Non-invasive fractional flow reserve tech developer CathWorks said yesterday it closed a $15.8 million Series B round of financing to support its real-time digital platform designed to determine FFR in cath labs.

The round was led by Quark Venture and Triventures and joined by Planven Investments, Pontifax, Corundum Open Innovation, BioStar Ventures and an unnamed strategic investor, the Israel-based company said.

CathWorks FFR platform is designed to be used in under 5 minutes and uses standard angiographic images, the company said. A proprietary set of algorithms are used to reconstruct the coronary tree in 3D to provide a full FF analysis of all visible coronary arteries simultaneously, CathWorks added.

“We are enthusiastic that CathWorks’ digital FFR platform can both improve patient care and reduce costs while enhancing workflow in the cath lab. By applying novel mathematical approaches to measuring flow reserve, Cathworks makes real time virtual FFR a reality. Clinical testing in more than 400 patients has made me confident in the sensitivity and specificity of the Cathworks product as compared to wire based FFR,” Triventures managing partner Dr. Peter Fitzgerald said in a prepared statement.

Funding from the round will support a global pivotal trial of the system and support FDA 510(k) submission in hopes of regulatory approval, CathWorks said. The company received CE Mark approval in the European Union earlier this year.

“FFR has become a standard in the enablement of evidence-based treatment in coronary catheterizations. We intend to make FFR accessible to more patients by facilitating its widespread application without the use of invasive wires or the infusion of adenosine. We are delighted to receive the support of such an experienced group of investors,” CathWorks CEO and founder Guy Lavi said in a press release.

Filed Under: Blood Management, Business/Financial News, Cardiovascular, Catheters Tagged With: cathworks

In case you missed it

  • Report: EtO blood levels higher in Illinois neighbors of Medline sterilization plant
  • FDA clears augmented glenoids for Shoulder Innovations system
  • McKesson names new chief information and technology officer
  • Imperative Care raises $85m
  • CMR Surgical appoints new CEO
  • Peregrine Ventures raises $115m
  • Roche wins CE Mark for blood glucose reading smartphone app
  • Cantel Medical beats The Street in Q1 results
  • FDA details framework for abbreviated 510(k) medical device review pathway
  • Drug or device? FDA loses this argument for now
  • Aptar wins FDA clearance for ready-to-use seizure treatment device
  • Aurora Bio touts PET radiotracer data
  • Medical device excise tax would reduce R&D spending, report says
  • Proteus Digital Health restructuring amid reported funding woes
  • GE Healthcare partnering on regenerative tissue manufacturing
  • Schiller issues field safety notice for Tempus LS defibrillators
  • Report: 3M may sell off its drug-delivery business for $1 billion

RSS From Medical Design & Outsourcing

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Popular Posts

  • Report: SEC probes GE Healthcare, Philips, Siemens in Chinese bribery scheme
  • Edwards Lifesciences warns against below-market mini-tender offer Edwards Lifesciences
  • J&J’s Ethicon files ITC complaint against Intuitive Surgical Intuitive Surgical's EndoWrist instruments
  • Auris Health loses motion to move Intuitive Surgical patent suit from Del. to Cali. Johnson & Johnson's Auris, Intuitive Surgical
  • Enable Injections inks deal with Sanofi for drug delivery platform enfuse-enable-injections
Tweets by @MassDevice
MDO ad

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS